Dr. Jie Jin:  the New JAK Inhibitor Jaktinib in the Treatment of Myelofibrosis (MF)

Dr. Jie Jin:  the New JAK Inhibitor Jaktinib in the Treatment of Myelofibrosis (MF)

The 28th European Hematology Association (EHA) Congress was held from June 8th to June 11th, 2023, in Frankfurt, Germany, in a hybrid format combining online and offline meetings. As the largest international conference in the field of European hematology, the EHA Congress covered a wide range of scientific topics, clinical and basic research, including both benign and malignant hematology, discussing the latest developments in the field. Regarding the treatment of Myelofibrosis (MF), several studies from Dr. Jie Jin's team at the First Affiliated Hospital of Zhejiang University (abstracts S212, P1201, and P1033) were selected for this congress. These studies focused on exploring the efficacy and safety of the new JAK inhibitor Jaktinib in the treatment of MF, attracting significant attention due to its clinical significance. In this regard, Oncology Frontier conducted an on-site interview with Professor Jin Jie and provided a brief explanation of this topic.
ESMO Expert Commentary | Roxadustat Non-inferior to Standard Treatment, Poised to Transform Clinical Practice in Chemotherapy-Induced Anemia

ESMO Expert Commentary | Roxadustat Non-inferior to Standard Treatment, Poised to Transform Clinical Practice in Chemotherapy-Induced Anemia

Platinum-based, taxane, anthracycline, and other chemotherapy drugs are commonly used in the treatment of various cancers such as breast and lung cancer. However, these chemotherapy agents, known marrow suppressors, can lead to chemotherapy-induced anemia (CIA), resulting in a decline in functional capacity and diminished quality of life for patients. This year's ESMO conference revealed the results of a Phase III clinical study on roxadustat in treating CIA in patients with non-myeloid malignancies, offering a more convenient treatment option for CIA patients. "Oncology Frontier" is honored to invite Professor Yongmei Yin from Jiangsu Provincial People's Hospital and Professor Jian Zhang from Fudan University Cancer Hospital to share insights into the current challenges in CIA treatment and the significance of this study for CIA patients.
ESMO Big Shot Interview | Professor Feng Wang: Significant Efficacy of Sintilimab Combined with Apatinib and Bevacizumab in the Treatment of MSS/pMMR Metastatic Colorectal Cancer, Promising Future

ESMO Big Shot Interview | Professor Feng Wang: Significant Efficacy of Sintilimab Combined with Apatinib and Bevacizumab in the Treatment of MSS/pMMR Metastatic Colorectal Cancer, Promising Future

The 2023 European Society for Medical Oncology (ESMO) Annual Meeting was held in Madrid, Spain from October 20 to 24. The Oncology Frontier Reporting Team delved into the frontiers of international advancements, witnessing the progress of China's anti-cancer efforts on the global stage. Professor Feng Wang from Sun Yat-sen University Cancer Center presented an important oral report at this conference. In an interview with "Oncology Frontier," Professor Feng Wang shared insights into two studies and highlights in the field of gastric cancer at the ESMO conference. This issue compiles relevant content for readers.
WCLC 2023 |Dr. Zhu Zhengfei: SBRT Combined with Dual Immune Checkpoint Inhibitors for Advanced NSCLC Achieves a Median OS of 34 Months

WCLC 2023 |Dr. Zhu Zhengfei: SBRT Combined with Dual Immune Checkpoint Inhibitors for Advanced NSCLC Achieves a Median OS of 34 Months

The 2023 World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC), was held in Singapore from September 9th to 12th. " Oncology Frontier" invited Zhu Zhengfei from Fudan University-affiliated Cancer Hospital to comment on the findings of the COSINR study.